aficamten
aficamten: 4 clinical trials tracked.
aficamten evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about aficamten, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (4)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Safety Endpoints
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
Primary endpoint: Incidence of adverse events observed during dosing of aficamten in patients with HCM